scholarly journals P-126 * NEOADJUVANT CHEMORADIATION VERSUS CHEMOTHERAPY FOLLOWED BY SURGERY FOR NON-SMALL-CELL LUNG CANCER: DOWNSTAGING FROM STAGE IIIA TO STAGE I

2014 ◽  
Vol 18 (suppl 1) ◽  
pp. S33-S34
Author(s):  
H. Melek ◽  
A. Demir ◽  
A. S. Bayram ◽  
B. Ozkan ◽  
G. Cetinkaya ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Neoadjuvant Chemoradiation ◽  
Small Cell ◽  
Stage I ◽  
Small Cell Lung ◽  
Stage Iiia

scholarly journals Improved Survival Associated with Neoadjuvant Chemoradiation in Patients with Clinical Stage IIIA(N2) Non–Small-Cell Lung Cancer

2013 ◽  
Vol 8 (7) ◽  
pp. 915-922 ◽  
Author(s):  
Matthew Koshy ◽  
Stacey A. Fedewa ◽  
Renu Malik ◽  
Mark K. Ferguson ◽  
Wickii T. Vigneswaran ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Clinical Stage ◽  
Neoadjuvant Chemoradiation ◽  
Small Cell ◽  
Small Cell Lung ◽  
Stage Iiia

scholarly journals Treatment and outcomes for early non-small-cell lung cancer: a retrospective analysis of a Portuguese hospital database

2021 ◽  
pp. LMT46
Author(s):  
Marta Soares ◽  
Luís Antunes ◽  
Patrícia Redondo ◽  
Marina Borges ◽  
Ruben Hermans ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Squamous Cell ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Stage I ◽  
Small Cell Lung ◽  
Stage Iiia ◽  
Iiia Nsclc ◽  
One Year

Aim: This observational study evaluated treatment patterns and survival for patients with stage I–IIIA non-small-cell lung cancer (NSCLC). Materials & methods: Adults newly diagnosed with NSCLC in 2012–2016 at IPO-Porto hospital were included. Treatment data were available for patients diagnosed in 2015–2016. Results: 495 patients were included (median age: 67 years). The most common treatments were surgery alone or with another therapy (stage I: 66%) and systemic anticancer therapy plus radiotherapy (stage II: 54%; stage IIIA: 59%). One-year OS (95% CI) for patients with stage I, II and IIIA NSCLC (diagnosed 2012–2016) were 92% (88–96), 71% (62–82) and 69% (63–75), respectively; one-year OS (95% CI) for treated patients with stage I–II or stage IIIA NSCLC (diagnosed 2015–2016) were 89% (81–97) and 86% (75–98) for non-squamous cell and 76% (60–95) and 49% (34–70) for squamous cell NSCLC. Conclusion: Treatment advances are strongly needed for stage I–IIIA NSCLC, especially for patients with squamous cell histology.

Sign in / Sign up

Export Citation Format

Share Document